To include your compound in the COVID-19 Resource Center, submit it here.

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still take a mezzanine round to clear the path for an IPO.

On Thursday, HotSpot Therapeutics Inc. said SR One led the series B

Read the full 573 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE